Wednesday, October 1, 2014
Inquirer Daily News

Wyeth accused of overcharging for drug

The Justice Dept. said the firm overcharged Medicaid for stomach-acid medicine. Wyeth defended its actions.

The government says Wyeth failed to offer Protonix at the same discount to Medicaid as it gave to hospitals.
The government says Wyeth failed to offer Protonix at the same discount to Medicaid as it gave to hospitals. J. B. REED / Bloomberg

WASHINGTON - The Justice Department yesterday accused Wyeth, one of the nation's biggest drugmakers, of cheating Medicaid programs out of hundreds of millions of dollars by overcharging for a stomach-acid drug.

The Justice Department and more than a dozen states - including Delaware - have joined in two whistle-blower lawsuits against the Madison, N.J.-based drug company filed in federal court in Massachusetts.

Wyeth has about 5,000 employees at facilities in Malvern and Collegeville, where it has its U.S. pharmaceutical headquarters.

Wyeth contends its pricing program is correct.

The government is seeking financial penalties against the company of up to three times the amount lost by Medicaid. And if a settlement is reached, the two whistle-blowers who filed the original suits likely would be entitled to some share of the amount.

The court papers contend that from 2000 to 2006, Wyeth offered steep discounts to thousands of hospitals for two versions of Protonix, a drug that suppresses stomach acid.

By law, manufacturers of brand-name drugs are required to offer the same rebates to state Medicaid programs that they provide to other customers, such as hospitals.

The government contends the maneuver helped the company avoid paying hundreds of millions of dollars in rebates to Medicaid, a health-care program for the poor that is financed by state and federal money.

"By offering massive discounts to hospitals, but then hiding that information from the Medicaid program, we believe Wyeth caused Medicaid programs throughout the country to pay much more for these drugs than they should have," Assistant Attorney General Tony West said in a statement.

In court papers, the government accused the drug company of bundling the intravenous version of Protonix with the oral version in sales packages to hospitals, in the hopes of making more money in the lucrative outpatient market.

Wyeth defended its pricing plan.

"The company believes that its pricing calculations were correct and intends to defend itself vigorously in these actions," said Doug Petkus, a Wyeth spokesman.

Wyeth's shares fell 50 cents to $44.37 in after-hours trading.

The states joining the lawsuit are Delaware, California, Florida, Illinois, Indiana, Louisiana, Massachusetts, New York, Michigan, Nevada, New Hampshire, Tennessee, Texas, Virginia, and Wisconsin, as well as the District of Columbia.

New York-based drugmaker Pfizer Inc. is in the process of acquiring Wyeth for more than $60 billion in a deal expected to close later this year.

Wyeth had disclosed in a filing with the Securities and Exchange Commission that the government intended to intervene in the case, Bloomberg News reported.

 

Devlin Barrett Associated Press